Discovery of Novel 4,5-Dihydropyrrolo[3,4-c]pyrazol-6(2H)-one-Based Tubulin Inhibitors Targeting Colchicine Binding Site with Potent Anti-Ovarian Cancer Activity.
{"title":"Discovery of Novel 4,5-Dihydropyrrolo[3,4-c]pyrazol-6(2H)-one-Based Tubulin Inhibitors Targeting Colchicine Binding Site with Potent Anti-Ovarian Cancer Activity.","authors":"Quanwei Yu,Yujie Liu,Zhijia Wang,Chengyong Wu,Ruofei Zhang,Lun Tan,Lele Zhang,Cuiyu Guo,Lantu Gou,Weimin Li,Yang He,Yuxi Wang","doi":"10.1021/acs.jmedchem.5c00014","DOIUrl":null,"url":null,"abstract":"To address the toxicity of current microtubule inhibitors, we employed the GeminiMol deep learning model to screen the Zinc20 database, identifying a novel 4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one scaffold (Y1) targeting the colchicine binding site. Subsequent optimization culminated in Y60s, a potent antiproliferative agent (SKOV3 IC50 = 0.025 μM) that inhibits clonogenic formation, migration, and invasion of ovarian cancer cells. Y60s inhibited tubulin polymerization which in turn induced G2/M arrest and apoptosis in SKOV3 cells. Y60s demonstrated potent antitumor activity without observable toxicity in an SKOV3 xenograft model. The cocrystal structure of Y8 in complex with tubulin was resolved, confirming the key binding mode of 4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one compounds. This work showcases Y60s as a promising novel tubulin inhibitor and highlights the utility of deep learning model for rapid identification of bioactive compounds from large chemical databases.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"17 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c00014","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
To address the toxicity of current microtubule inhibitors, we employed the GeminiMol deep learning model to screen the Zinc20 database, identifying a novel 4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one scaffold (Y1) targeting the colchicine binding site. Subsequent optimization culminated in Y60s, a potent antiproliferative agent (SKOV3 IC50 = 0.025 μM) that inhibits clonogenic formation, migration, and invasion of ovarian cancer cells. Y60s inhibited tubulin polymerization which in turn induced G2/M arrest and apoptosis in SKOV3 cells. Y60s demonstrated potent antitumor activity without observable toxicity in an SKOV3 xenograft model. The cocrystal structure of Y8 in complex with tubulin was resolved, confirming the key binding mode of 4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one compounds. This work showcases Y60s as a promising novel tubulin inhibitor and highlights the utility of deep learning model for rapid identification of bioactive compounds from large chemical databases.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.